Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
Due to its common dysregulation in epithelial-based cancers and extensive characterization of its role in tumor growth, epidermal growth factor receptor (EGFR) is a highly validated target for anticancer therapies. There has been particular interest in the development of monoclonal antibodies (mAbs)...
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
National Academy of Sciences (U.S.)
2011
|
| Online Access: | http://hdl.handle.net/1721.1/66709 https://orcid.org/0000-0002-1545-1651 https://orcid.org/0000-0003-2398-5896 |